tbuckley/cabot-search huggingface dataset:
Myelography
Authors: Bernard S. Epstein
Journal: JAMA (1975)

The third edition of<i>Myelography</i>again is directed to investigation of lesions impinging into or involving the subarachnoid spaces of the spinal canal and the posterior fossa, mainly by positive contrast (Pantopaque) examinations. As in the second edition, the contents includes chapters on various contrast media, technique, radiation dosage, normal spinal anatomy, the normal myelogram, artifacts, and a note on complications and limitations of the method. Chapters on the pathologic myelogram review tumors, trauma, congenital lesions, inflammations, discal herniations, miscellaneous nonneoplastic lesions, and diskography. These are very much like those in the second edition. However, the section on spondylosis and the narrow spinal canal has been revised, and considerable material referable to the posterior fossa and some on tumors has been added. About 20% of the illustrations pertaining to these chapters have been replaced. All the excellent diagrams in the second edition have been retained, and a few new ones
Correction: Ethics of Placebo-Controlled Trials
Journal: Annals of Internal Medicine (2000)

Corrections7 November 2000Correction: Ethics of Placebo-Controlled TrialsFREESearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-9-200011070-00038 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In the editorial by Simon published in the 19 September issue (1), the source of two quotations attributed to Dr. Kenneth Rothman was identified incorrectly. These quotations were “You could torture someone for 10 minutes, and he would recover, but that doesn't mean it's a great idea … you're supposed to be acting in the best interest of the patient,” and “[placebo-controlled trials result from] a misplaced emphasis on statistical significance testing. They never know how effective any drug is because they simply ask, ‘Is it or isn't it effective? Is it significantly better than placebo?’”. Both quotations were actually taken from the Current Clinical Issues article by Tom Reynolds that also appeared in the 19 September issue of the journal (2), rather than from the article by Rothman and Michels (3) cited in the Simon editorial.References1. Simon R. Are placebo-controlled trials ethical or needed when alternative treatment exists? [Editorial]. Ann Intern Med. 2000;133:474-5. LinkGoogle Scholar2. Reynolds T. The ethics of placebo-controlled trials. Ann Intern Med. 2000;133:491-2. LinkGoogle Scholar3. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med. 1994;331:394-8. CrossrefMedlineGoogle Scholar Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Ethics of Placebo-Controlled Trials Tom Reynolds Are Placebo-Controlled Clinical Trials Ethical or Needed When Alternative Treatment Exists? Richard Simon Metrics 7 November 2000Volume 133, Issue 9Page: 754KeywordsDrugs ePublished: 7 November 2000 Issue Published: 7 November 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Uncovering a Culprit in CAR-T Resistance
Journal: Cancer Discovery (2020)

Abstract Preclinical findings from Stanford University may help explain the lack of efficacy with CAR T-cell therapies in some patients with large B-cell lymphomas. The researchers pinpointed the CD58–CD2 axis as a novel resistance mechanism, then figured out how next-generation CAR T cells could be engineered to overcome this issue.
Genetic testing of families with hereditary diseases
Authors: O. I. Olopade
Journal: JAMA (1996)

<h3>To the Editor.</h3> —Dr Lerman and colleagues<sup>1</sup>recently provided data on the uptake of<i>BRCA1</i>testing in adult members of families with<i>BRCA1</i>-linked hereditary breast-ovarian cancer. However, in their discussion, the authors underscored the value of personal access to genetic education in helping patients form opinions about testing. It is not surprising that only 43% of their study subjects requested<i>BRCA1</i>results, probably because of the counseling model used.<sup>2</sup>In my experience, the relationships within some families are so strained that individual members would rather not interact with some of their relatives. What is remarkable about the study by Lerman et al is that 115 (99%) of 116 individuals who participated in pretest education elected to receive their test results. These data strengthen the argument for personalized counseling.<sup>3</sup> A recent review of our Cancer Risk Clinic program identified access to counseling and education as one of
Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity
Authors: Saborni Chakraborty, Joseph C. Gonzalez, Benjamin L. Sievers, Vamsee Mallajosyula, Srijoni Chakraborty, Megha Dubey, Usama Ashraf, Bowie Yik-Ling Cheng, Nimish Kathale, Kim Quyen Thi Tran, Courtney Scallan, Aanika Sinnott, Arianna Cassidy, Steven T. Chen, Terri Gelbart, Fei Gao, Yarden Golan, Xuhuai Ji, Seunghee Kim-Schulze, Mary Prahl, Stephanie L. Gaw, Sacha Gnjatic, Thomas U. Marron, Miriam Merad, Prabhu S. Arunachalam, Scott D. Boyd, Mark M. Davis, Marisa Holubar, Chaitan Khosla, Holden T. Maecker, Yvonne Maldonado, Elizabeth D. Mellins, Kari C. Nadeau, Bali Pulendran, Upinder Singh, Aruna Subramanian, Paul J. Utz, Robert Sherwood, Sheng Zhang, Prasanna Jagannathan, Gene S. Tan, Taia T. Wang
Journal: Science Translational Medicine (2022)

A damaging inflammatory response is implicated in the pathogenesis of severe coronavirus disease 2019 (COVID-19), but mechanisms contributing to this response are unclear. In two prospective cohorts, early non-neutralizing, afucosylated immunoglobulin G (IgG) antibodies specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were associated with progression from mild to more severe COVID-19. To study the biology of afucosylated IgG immune complexes, we developed an in vivo model that revealed that human IgG-Fc-gamma receptor (FcγR) interactions could regulate inflammation in the lung. Afucosylated IgG immune complexes isolated from patients with COVID-19 induced inflammatory cytokine production and robust infiltration of the lung by immune cells. In contrast to the antibody structures that were associated with disease progression, antibodies that were elicited by messenger RNA SARS-CoV-2 vaccines were highly fucosylated and enriched in sialylation, both modifications that reduce the inflammatory potential of IgG. Vaccine-elicited IgG did not promote an inflammatory lung response. These results show that human IgG-FcγR interactions regulate inflammation in the lung and define distinct lung activities mediated by the IgG that are associated with protection against, or progression to, severe COVID-19.
Hepatology Highlights
Authors: Muzammil Muhammad Khan, Maria Alejandra Luna‐Cuadros, Daryl T.Y. Lau, Tejasav S. Sehrawat, Ojasav Sehrawat, Robert E. Schwartz, Anthony J. Choi, Robert S. Brown, Gopanandan Parthasarathy, Enis Kostallari, Nidhi Jalan‐Sakrikar, David M. Salerno, Chaitanya Allamneni, Ravi S. Vora, Jessica L. Maiers
Journal: Hepatology (2021)
<i>ERJ</i>Podcast June 2020: The natural history of progressive fibrosing ILD
Journal: European Respiratory Journal (2020)

As part of the June issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief Editor Martin Kolb interviews Kevin K. Brown (National Jewish Health, Denver, CO, USA) and Athol U. Wells (Royal Brompton Hospital, London, UK) about analyses of data from the INBUILD and INPULSIS trials suggesting that progressive fibrosing interstitial lung diseases other than idiopathic pulmonary fibrosis have a clinical course similar to IPF.
The Cover
Authors: Frederick Butzen
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Efficacy of MDX-124, a novel anti-annexin-A1 antibody, in preclinical models of pancreatic cancer.
Authors: Fiona C. Dempsey, Hussein Al-Ali, Scott J. Crichton, Charlene Fabian, Emily Roberts, Chris Pepper, Michael C. Schmid, Christopher N. Parris
Journal: Journal of Clinical Oncology (2022)

590 Background: Pancreatic cancer is a highly fatal disease with poor survival and response to both chemotherapy and immunotherapy. Novel approaches to treat this disease are urgently required. Annexin-A1 (ANXA1) is secreted in response to several physiological stimuli where it activates formyl peptide receptors (FPR1/2) triggering multiple oncogenic processes. High ANXA1 expression in pancreatic cancer patients is associated with poor overall survival, and influences cancer progression, drug sensitivity, migration and invasion. MDX-124 is a novel humanized antibody targeting ANXA1 and we have previously presented data demonstrating its significant antiproliferative activity. Here we present further data showing the efficacy of MDX-124 in several preclinical models of pancreatic cancer. Methods: In-vitro models utilized MIA PaCa-2, PANC-1 or BxPC-3 human pancreatic cancer cell lines. Cell cycle progression was evaluated by measuring changes in DNA content via flow cytometry. Pancreatic cancer cell viability following incubation with MDX-124 (0-10 µM) and 5FU (IC 50 ) was assessed via MTT assay. A transwell migration assay was used to evaluate the effect of MDX-124 (0-50 µM) on pancreatic cancer cell migration. In-vivo efficacy was evaluated using an orthotopic mouse model of metastatic pancreatic cancer (FC1242 luc/zsGreen ; KPC-derived cell line) with bioluminescent imaging used to quantify the incidence and burden of lung metastases. Results: When compared to untreated MIA PaCa-2 pancreatic cancer cells, MDX-124 treatment decreased the proportion of cells in S-phase by 29% and G2 phase by 9.1%, with a concomitant increase in G1 of 38.1%. This occurred in a dose-dependent manner and is consistent with an MDX-124 mediated increase in cell cycle arrest. MDX-124 significantly reduced the viability of MIA PaCa-2 and PANC-1 cell lines versus an IgG control in a dose-dependent manner. Additionally in these two cell lines, combination of MDX-124 with 5FU (IC 50 ) had a significant synergistic impact reducing cancer cell viability by 99.8% and 91.2% respectively. Furthermore, MDX-124 significantly reduced the migratory ability of MIA PaCa-2 and BxPC-3 pancreatic cancer cells. In the orthotopic model of metastatic pancreatic cancer, the murine analog of MDX-124 (MDX-001), markedly reduced both the incidence and size of lung metastases. Conclusions: MDX-124 demonstrated significant anti-tumor efficacy in several preclinical models of pancreatic cancer as a single agent, with increased potency observed when used in combination with 5FU. Medannex will initiate a First-In-Human study in Q4 2021 to evaluate MDX-124 in solid malignancies, including pancreatic cancer.
Endoscopic removal of an ulcerated appendiceal stump
Authors: L. C. Maas
Journal: JAMA (1978)

INVERTED appendiceal stump is part of the differential diagnosis of a radiologically demonstrated cecal mass in patients after appendectomy. We report the colonoscopic removal of an inverted appendiceal stump employing standard snare and electrocautery technique. Of special interest, the appendiceal stump was invaded by unusual fungi producing an ulcerated-granulomatous inflammatory reaction. <h3>Report of a Case</h3> A 23-year-old man was admitted with a ten-month history of intermittent right lower quadrant abdominal pain occasionally associated with black, tarry stools. On the day of admission, after ingestion of considerable alcohol, the patient had severe epigastric pain and hematemesis. Past medical history included recurrent calcium and uric acid nephrolithiasis for six years and an appendectomy one year ago. The latter was uneventful with complete recovery. The physical examination was unremarkable except for mild epigastric and right lower quadrant tenderness, an appendectomy scar, and guaiac-positive stools. The complete blood cell count, ESR, and multiphasic profile
Association News
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pathologic Basis of Disease.
Journal: Annals of Internal Medicine (1975)

This volume presents abstracts of the literature published during the first 10 years of realistic research into human viral hepatitis.Unfortunately, the abstracts have not been arranged chronologically, and this, taken together with the lack of an author index, means that finding a particular abstract can be difficult.This volume is of outstanding value to those working in the hepatitis field, and it is only to be re- gretted that more attention was not paid to the convenience of the user.
Books Received
Authors: Chiara Brombin, Ernesto Caffo, J. Wiltink, P. Bech, H.V. Hansen, L.V. Kessing, C. Faravelli, C. Ravaldi, E. Truglia, T. Zucchi, F. Cosci, V. Ricca, Johann F. Kinzl, Katharina Hauer, Christian Traweger, Ingrid Kiefer, Chiara Ruini, Carlotta Belaise, A. Dippel, M. Szczepanski, R. Thiede, Yi-Ching Lu, M.E. Beutel, Giovanni A. Fava, Silvana Grandi, Stefania Fabbri, Naike Panattoni, Elisabetta Gonnella, Isaac Marks, Nina Rieckmann, Matthew M. Burg, William Gerin, William F. Chaplin, Lynn Clemow, Karina W. Davidson, Johan Denollet, Jacqueline J. Strik, Richel Lousberg, Adriaan Honig, Bih-Ching Shu, Yong-Yuan Chang, For-Wey Lung, Boudewijn van Houdenhove, Victor I. Spoormaker, Jan van den Bout
Journal: Psychotherapy and Psychosomatics (2006)
TCT- 610 Prospective, Multi-Center Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold: Imaging Outcomes and 2-Year Clinical Results
Authors: Alexandre Abizaid, Joachim Schofer, Michael Maeng, Bernhard Witzenbichler, Roberto Botelho, John A. Ormiston, Ricardo A. Costa, Jose d Costa, Daniel Chamié, Andrea Abizaid, Yan John, Vinayak Bbhat, lynn morrison, Sara Toyloy, Stefan Verheye
Journal: Journal of the American College of Cardiology (2014)
Obituaries
Journal: JAMA (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In patients with chronic heart failure echo-doppler monitoring is more accurate than physical examination to detect severe hemodynamic alterations Soccorso Capomolla, Oreste Febo, Giampaolo Guazzotti, Angelo Caporotondi, Marco Gnemmi, Andrea Mortara, Franco Cobelli, Giandomenico Pinna, Roberto Maestri. Fondazione S. Maugeri, IRCCS, Pavia, Montescano(Pavia), Italy
Journal: Journal of the American College of Cardiology (2001)
COVID-19 will not leave behind refugees and migrants
Authors: None The Lancet
Journal: The Lancet (2020)

Never has the "leave no one behind" pledge felt more urgent. As nations around the world implement measures to control the spread of SARS-CoV-2, including lockdowns and restrictions on individuals' movements, they must heed their global commitments. When member states adopted the UN 2030 Agenda for Sustainable Development, they promised to ensure no one will be left behind. Chief among the world's most vulnerable people are refugees and migrants. The COVID-19 crisis puts these groups at enormous risk.
Response to Kunos et al. and Lotersztajn and Mallat
Authors: Simeng Wang, Qingzhang Zhu, Guosheng Liang, Tania Franks, Magalie Boucher, Kendra K Bence, Mingjian Lu, Carlos M Castorena, Shangang Zhao, Joel K Elmquist, Philipp E Scherer, Jay D Horton
Journal: Journal of Clinical Investigation (2022)
Impact of nuclear factor of activated T cells (NFAT) families as a poor prognostic factor in pancreatic cancer patients.
Authors: Yuto Kamioka, Yukihiko Hiroshima, Shinnosuke Kawahara, Masaaki Murakawa, Naoto Yamamoto, Hiroshi Tamagawa, Takashi Oshima, Yohei Miyagi, Yasushi Rino, Soichiro Morinaga
Journal: Journal of Clinical Oncology (2022)

584 Background: Pancreatic cancer microenvironment is crucial in cancer development, and cancer-stromal interactions have been recognized as important targets for cancer therapy. Nuclear factor of activated T-cells (NFAT) has been found in T cells as a transcriptional activator of IL-2, and known to be involved in various processes including the immune system. In cancer tissues, NFAT has been reported to be involved in metastasis. In breast and colorectal cancers, NFATc2 and NFAT5 have been reported to interact with integrins to promote cancer cell migration. On the other hand, in pancreatic cancer, NFAT5 has been reported to be a poor prognostic factor via regulation of PGK1 transcription. In the present study, we evaluated the expression of NFATc2 and NFAT5 in pancreatic cancer and examined their relationship with prognosis. Methods: One hundred and sixty five pancreatic cancer patients who underwent curative-intrent resection at our hospital between 2010 and 2020 were included in this study. We performed immunostaining for NFATc2 and NFAT5 using the tissue micro array. We evaluated the expression of NFATc2 and NFAT5 protein and examined their correlation with clinicopathological factors. Results: Of the 165 pancreatic cancer cases, we detected increased NFATc2 protein expression in cytoplasm of cancer cells in 53 cases (32.1%) and NFAT5 in 104 cases (63.0%), and NFATc2/NFAT5 co-expression in 43 cases (26.1%). NFATc2 expression was not correlated with any clinicopathological factors, NFAT5 expression was correlated with venous invasion (p = 0.047), and NFATc2/NFAT5 co-expression was slightly correlated with Stage (p = 0.054). Relapse free survival (RFS) was estimated in all 165 patients. There was no significant difference for RFS in either NFATc2-high group or NFAT5-high group (p = 0.314 or p = 0.574), however, NFATc2/NFAT5 co-expression group showed significantly poor RFS (p = 0.023). Overall survival (OS) was also estimated in all 165 patients. There was no significant difference for OS in either NFATc2-high group or NFAT5-high group (p = 0.146 or p = 0.529), however, NFATc2/NFAT5 co-expression group showed significantly poor survival (p = 0.006). In multivariate analysis, lymphatic invasion, curability and NFATc2/NFAT5 co-expression were independent prognostic factors for RFS, and lymphatic invasion, curability, presence of adjuvant therapy and NFATc2/NFAT5 co-expression were independent prognostic factors for OS. Conclusions: In pancreatic cancer, NFATc2/NFAT5 co-expression was suggested to be involved in the critical process of pancreatic cancer progression, and may be a novel therapeutic target.
Manuscripts Approved For JNCI, July-August 1971
Journal: JNCI Journal of the National Cancer Institute (1971)

Manuscripts Approved For JNCI, July-August 1971 JNCI: Journal of the National Cancer Institute, Volume 47, Issue 3, September 1971, Pages 731–732, https://doi.org/10.1093/jnci/47.3.731 Published: 01 September 1971
Dissimilar Control Interventions in Clinical Trials Undermine Interpretability
Authors: David Hohenschurz-Schmidt, Jerry Draper-Rodi, Lene Vase
Journal: JAMA Psychiatry (2022)

To the Editor Ashar and colleagues1 published a trial of pain reprocessing therapy (PRT) for people with chronic back pain. Translating contemporary evidence from pain research and psychology into a novel therapeutic program, the study was rightly met with a lot of interest.
Laboratory Course in Histology.
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal